Progyny, Inc. Files 8-K Report
Ticker: PGNY · Form: 8-K · Filed: May 22, 2024 · CIK: 1551306
| Field | Detail |
|---|---|
| Company | Progyny, Inc. (PGNY) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $100 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, SEC
TL;DR
Progyny filed an 8-K, no major news, just standard reporting.
AI Summary
On May 22, 2024, Progyny, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not reporting on specific material events like a merger, acquisition, or bankruptcy. The report confirms Progyny, Inc.'s principal executive offices are located at 1359 Broadway, New York, NY 10018.
Why It Matters
This 8-K filing serves as a notification to the SEC and investors about the company's reporting status, ensuring transparency regarding any significant events or updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material risks or adverse information.
Key Players & Entities
- Progyny, Inc. (company) — Registrant
- 1359 Broadway, New York, NY 10018 (location) — Principal Executive Offices
- May 22, 2024 (date) — Date of report
FAQ
What is the purpose of this 8-K filing for Progyny, Inc.?
This 8-K filing is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating Progyny, Inc. is reporting under 'Other Events'.
When was this 8-K report filed by Progyny, Inc.?
The report was filed on May 22, 2024.
What is the address of Progyny, Inc.'s principal executive offices?
The address of Progyny, Inc.'s principal executive offices is 1359 Broadway, New York, New York 10018.
What is Progyny, Inc.'s state of incorporation?
Progyny, Inc. is incorporated in Delaware.
Does this filing indicate any specific material event for Progyny, Inc.?
The filing indicates the report is for 'Other Events' and does not specify a particular material event such as a merger, acquisition, or bankruptcy, suggesting it may be for routine disclosures or updates.
Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-22 17:06:04
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value per share PGNY The Nasdaq Gl
- $100 million — repurchase program to repurchase up to $100 million of its common stock. This follows the p
Filing Documents
- pgny-20240522.htm (8-K) — 24KB
- 0001551306-24-000107.txt ( ) — 143KB
- pgny-20240522.xsd (EX-101.SCH) — 2KB
- pgny-20240522_lab.xml (EX-101.LAB) — 21KB
- pgny-20240522_pre.xml (EX-101.PRE) — 12KB
- pgny-20240522_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Progyny, Inc. (the " Company " ) announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. This follows the program that was previously announced on February 29, 2024. The program will be funded through available cash balances. Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending on stock price, market conditions and other factors deemed relevant in the Company's sole discretion. The program may be suspended or discontinued at any time. There can be no assurances as to how many shares the Company will repurchase, if any, or at what prices any purchases will be made.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Progyny, Inc. Dated: May 22, 2024 By: /s/ Peter Anevski Peter Anevski Chief Executive Officer